Results 181 to 190 of about 1,494 (190)

CD123-Targeted Therapy Shows Long-Term Benefit for BPDCN Patients

Oncology Times, 2022
openaire   +1 more source

Clinical Hold Lifted on UCART123 Trials for AML/BPDCN

Oncology Times, 2017
openaire   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management

American Journal of Hematology
Shai Shimony, Andrew A Lane, Marlise R Luskin   +2 more
exaly  

Primary Cutaneous Presentation of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

European Journal of Cancer
Ch. Oikonomidi, Anthi Bouchla, Kyriaki Lampadaki, Leonidas Marinos, Evangelia Papadavid, Vasiliki Pappa   +5 more
openaire   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCNs)

openaire   +1 more source

CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

Leukemia Research
Brent T Tan, Naveen Pemmaraju, Atif Saleem   +2 more
exaly  

Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival

Blood Advances
Shai Shimony, Andrew A Lane, Marlise R Luskin   +2 more
exaly  

Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations

Leukemia and Lymphoma
Andrew A Lane, David Rizzieri, Raajit K Rampal   +2 more
exaly  

Infiltrative plaques on the temple. Blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Pediatric dermatology, 2015
Nan, Sheng, Jing-shu, Xiong, Yi-hua, Wang, Hao, Chen, Jian-fang, Sun   +4 more
openaire   +1 more source

The critical role of flow cytometry in the diagnosis of a BPDCN.

Calliauw, Evan, Bouteille, Sandrine Paula, Simke, Demeester, Evenepoel, Anton, Vercruyssen, Jill, Linskens, Eleni   +5 more
openaire   +1 more source